SCHEDULE: Qiming Entities File Joint Schedule 13G

Several Qiming entities have entered into a joint filing agreement to collectively report their beneficial ownership of Alamar Biosciences, Inc. common stock.

Summary

• This filing is a Schedule 13G, indicating beneficial ownership of Alamar Biosciences, Inc. common stock by several Qiming entities.
• The Qiming entities involved include Qiming Corporate GP VI, Ltd, Qiming Venture Partners VI, L.P., Qiming Managing Directors Fund VI, L.P., Qiming GP VIII, LLC, Qiming Venture Partners VIII Investments, LLC, Qiming GP VIII-HC, LLC, and Qiming Venture Partners VIII-HC, L.P.
• A Joint Filing Agreement dated August 11, 2026, formalizes the agreement for these entities to jointly file future amendments to the Schedule 13G.
• The reporting date for the event requiring this filing is June 30, 2026.
• The total beneficial ownership reported by these entities aggregates to 10.2% of Alamar Biosciences, Inc.'s common stock, based on 69,311,186 shares outstanding as of April 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily concerns a joint filing agreement and does not contain operational or financial performance updates.

Positives

• Clear disclosure of significant beneficial ownership by Qiming entities.
• Formalized joint filing agreement ensures coordinated reporting of future ownership changes.

Negatives

• The filing does not provide any operational or financial performance data for Alamar Biosciences, Inc.
• The information is purely related to ownership and does not offer insights into the company's business.

Risks

• Potential for significant ownership changes by these entities could impact market dynamics.
• The concentration of ownership by a single investment group could influence corporate governance decisions.

Future Outlook

No forward-looking statements or guidance are provided in this filing, as it pertains to ownership disclosure.

Industry Context

StockSavvy.ai notes that this filing reflects the typical reporting requirements for significant institutional investors, such as venture capital firms like Qiming, when their ownership stake in a public company crosses certain thresholds.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership blocks held by Qiming entities.
• Management: Awareness of a substantial investor group's collective stake and potential influence.

Next Steps

• The Qiming entities will jointly file any future amendments to this Schedule 13G.
• This agreement can be terminated by any signatory providing written notice to the other parties.

Key Dates

Keywords

Alamar Biosciences, Schedule 13G, Beneficial Ownership, Qiming, Venture Capital, Investment Group, Cayman Islands